Developments in gene therapy for muscular dystrophy

Dennis Hartigan-O'Connor, Jeffrey S. Chamberlain

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Gene therapy for muscular dystrophy (MD) presents significant challenges, including the large amount of muscle tissue in the body, the large size of many genes defective in different muscular dystrophies, and the possibility of a host immune response against the therapeutic gene. Overcoming these challenges requires the development and delivery of suitable gene transfer vectors. Encouraging progress has been made in modifying adenovirus (Ad) vectors to reduce immune response and increase capacity. Recently developed gutted Ad vectors can deliver full-length dystrophin cDNA expression vectors to muscle tissue. Using muscle-specific promoters to drive dystrophin expression, a strong immune response has not been observed in mdx mice. Adeno-associated virus (AAV) vectors can deliver small genes to muscle without provocation of a significant immune response, which should allow long-term expression of several MD genes. AAV vectors have also been used to deliver sarcoglycan genes to entire muscle groups. These advances and others reviewed here suggest that barriers to gene therapy for MD are surmountable. (C) 2000 Willey-Liss, Inc.

Original languageEnglish (US)
Pages (from-to)223-238
Number of pages16
JournalMicroscopy Research and Technique
Volume48
Issue number3-4
StatePublished - 2000
Externally publishedYes

Fingerprint

gene therapy
Gene therapy
muscular dystrophy
Muscular Dystrophies
Genetic Therapy
genes
muscles
Dependovirus
Muscle
Genes
immune response
dystrophin
Muscles
adenoviruses
Adenoviridae
Dystrophin
muscle tissues
viruses
Viruses
genetic vectors

Keywords

  • AAV
  • Adenovirus
  • Duchenne
  • Dystrophin
  • Gutless
  • Gutted
  • Helper- dependent
  • Lentivirus
  • Limb-girdle
  • Vector

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Anatomy
  • Instrumentation

Cite this

Developments in gene therapy for muscular dystrophy. / Hartigan-O'Connor, Dennis; Chamberlain, Jeffrey S.

In: Microscopy Research and Technique, Vol. 48, No. 3-4, 2000, p. 223-238.

Research output: Contribution to journalArticle

Hartigan-O'Connor, Dennis ; Chamberlain, Jeffrey S. / Developments in gene therapy for muscular dystrophy. In: Microscopy Research and Technique. 2000 ; Vol. 48, No. 3-4. pp. 223-238.
@article{dc42601314a541e7ad1ac584e88a5df3,
title = "Developments in gene therapy for muscular dystrophy",
abstract = "Gene therapy for muscular dystrophy (MD) presents significant challenges, including the large amount of muscle tissue in the body, the large size of many genes defective in different muscular dystrophies, and the possibility of a host immune response against the therapeutic gene. Overcoming these challenges requires the development and delivery of suitable gene transfer vectors. Encouraging progress has been made in modifying adenovirus (Ad) vectors to reduce immune response and increase capacity. Recently developed gutted Ad vectors can deliver full-length dystrophin cDNA expression vectors to muscle tissue. Using muscle-specific promoters to drive dystrophin expression, a strong immune response has not been observed in mdx mice. Adeno-associated virus (AAV) vectors can deliver small genes to muscle without provocation of a significant immune response, which should allow long-term expression of several MD genes. AAV vectors have also been used to deliver sarcoglycan genes to entire muscle groups. These advances and others reviewed here suggest that barriers to gene therapy for MD are surmountable. (C) 2000 Willey-Liss, Inc.",
keywords = "AAV, Adenovirus, Duchenne, Dystrophin, Gutless, Gutted, Helper- dependent, Lentivirus, Limb-girdle, Vector",
author = "Dennis Hartigan-O'Connor and Chamberlain, {Jeffrey S.}",
year = "2000",
language = "English (US)",
volume = "48",
pages = "223--238",
journal = "Microscopy Research and Technique",
issn = "1059-910X",
publisher = "Wiley-Liss Inc.",
number = "3-4",

}

TY - JOUR

T1 - Developments in gene therapy for muscular dystrophy

AU - Hartigan-O'Connor, Dennis

AU - Chamberlain, Jeffrey S.

PY - 2000

Y1 - 2000

N2 - Gene therapy for muscular dystrophy (MD) presents significant challenges, including the large amount of muscle tissue in the body, the large size of many genes defective in different muscular dystrophies, and the possibility of a host immune response against the therapeutic gene. Overcoming these challenges requires the development and delivery of suitable gene transfer vectors. Encouraging progress has been made in modifying adenovirus (Ad) vectors to reduce immune response and increase capacity. Recently developed gutted Ad vectors can deliver full-length dystrophin cDNA expression vectors to muscle tissue. Using muscle-specific promoters to drive dystrophin expression, a strong immune response has not been observed in mdx mice. Adeno-associated virus (AAV) vectors can deliver small genes to muscle without provocation of a significant immune response, which should allow long-term expression of several MD genes. AAV vectors have also been used to deliver sarcoglycan genes to entire muscle groups. These advances and others reviewed here suggest that barriers to gene therapy for MD are surmountable. (C) 2000 Willey-Liss, Inc.

AB - Gene therapy for muscular dystrophy (MD) presents significant challenges, including the large amount of muscle tissue in the body, the large size of many genes defective in different muscular dystrophies, and the possibility of a host immune response against the therapeutic gene. Overcoming these challenges requires the development and delivery of suitable gene transfer vectors. Encouraging progress has been made in modifying adenovirus (Ad) vectors to reduce immune response and increase capacity. Recently developed gutted Ad vectors can deliver full-length dystrophin cDNA expression vectors to muscle tissue. Using muscle-specific promoters to drive dystrophin expression, a strong immune response has not been observed in mdx mice. Adeno-associated virus (AAV) vectors can deliver small genes to muscle without provocation of a significant immune response, which should allow long-term expression of several MD genes. AAV vectors have also been used to deliver sarcoglycan genes to entire muscle groups. These advances and others reviewed here suggest that barriers to gene therapy for MD are surmountable. (C) 2000 Willey-Liss, Inc.

KW - AAV

KW - Adenovirus

KW - Duchenne

KW - Dystrophin

KW - Gutless

KW - Gutted

KW - Helper- dependent

KW - Lentivirus

KW - Limb-girdle

KW - Vector

UR - http://www.scopus.com/inward/record.url?scp=0033964678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033964678&partnerID=8YFLogxK

M3 - Article

C2 - 10679969

AN - SCOPUS:0033964678

VL - 48

SP - 223

EP - 238

JO - Microscopy Research and Technique

JF - Microscopy Research and Technique

SN - 1059-910X

IS - 3-4

ER -